-

EDI Toolkit and Resources
We recently add a new page to our website! The Equity, Diversity and Inclusion (EDI) in Clinical Trials contains EDI resources developed by 3CTN and our recently completed EDI Toolkit.
-

-

A Tool for Patient Partner Development
Embedding Patient and Public Involvement (PPI) as a means for helping assure patient values and perspectives are reflected in clinical trials conduct has been a founding priority of the Canadian Cancer Clinical Trials Network (3CTN). Our community of Patient Representatives guide and support trial activities locally at cancer centres and centrally through participation in Network
-

3CTN’s Executive Director talks CRAFT DCT model development
Stephen Sundquist joins the Decentralized: The Decentralized Trials and Research Podcast to talk about the CRAFT DCT model development and implementation strategy and Bianka Courcelle from CHU Sainte-Justine, shares the PI site perspective in implementing these trials.
-

Canada needs a national system for cancer clinical trials
Toronto Star – Clinical trials are the most effective means of ensuring we have better cancer treatments. Such an investment would help overcome many hurdles facing clinical trials – from underfunding and suboptimal testing capacity to inefficient and costly regulatory processes. By Janet Dancey Contributor “A bad system will beat a good person every time.” William Edwards Deming
-

impACCT Virtual Rounds Winter Session 2024
When: Thursday, March 7, 2024 12:00 pm -1:15 pm ESTTrial #1: OCOG-2022-ROSALIE: Radiation OmisSion in PAtients With CLinically Node Negative Breast Cancer Undergoing Lumpectomy and With a PathologIc Complete REsponse After Neoadjuvant Chemotherapy https://clinicaltrials.gov/study/NCT05866458 Speaker: Dr. Elena Parvez, MD, Assistant Professor, Department of Surgery, McMaster University; Surgical Oncologist at the Juravinski Hospital and Cancer Centre
-

2022-23 3CTN Impact Report
Check out the accomplishments of Network Sites and the 3CTN Coordinating Centre.
-

-

impACCT Virtual Rounds Fall Session 2023
When: Thursday, Sept 28, 2023, 12:00 pm -1:00 pm EDT Trial #1: (UHN) PLAN Prevention of persistent pain with Lidocaine infusions in breast cancer surgery Speaker: James Khan, MD, Assistant Professor and Clinician-Scientist, Department of Anesthesia and Pain Medicine, University of Toronto. Trial #2: (CCTG) CRC.10 / NRG-GI008 A phase II/III study to determine chemotherapy recommendations
-


